Revive Therapeutics

Revive Therapeutics Ltd. (TSX-V: RVV) (OTCQB: RVVTF) (FSE: 31R) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets by identifying and investigating potential therapies targeting the endocannabinoid system, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities.

<div>Toronto-based Revive Therapeutics is a cannabinoid pharmaceutical company developing therapeutics for rare and infectious diseases. With the acquisition of Psilocin Pharma in February 2020, the company entered the psychedelic market and intends to advance psilocybin-based therapeutics targeting various diseases. The acquisition gave Revive ownership of the intellectual property for psilocybin-based manufacturing methods. Revive Therapeutics&rsquo; non-psychedelic drug candidates include Bucillamine to treat Covid-19 and liver diseases.&nbsp;</div>

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

<div>Revive Therapeutics Ltd. is a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and psychedelic treatments. The company's primary areas of focus include the potential use of Bucillamine for treating severe influenza and Covid-19, as well as the development of psilocybin-based therapeutics for various diseases and disorders. Revive is advancing a psychedelic pharmaceuticals pipeline, which includes a proprietary oral thin film delivery technology for psilocybin-based therapeutics developed in collaboration with the University of Wisconsin-Madison. The company is also working on a novel biosynthetic version of psilocybin using a natural biosynthesis enzymatic platform developed by Dr. Gavin Williams at North Carolina State University.</div>

Specialty Life Sciences Company

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials - Psyence Group (OTC:PSYGF), Revive Therapeutics (OTC:RVVTF)

Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), ATAI Life Sciences (NASDAQ:ATAI)

Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

Revive Therapeutics Announces Collaboration and Royalty Agreement With Richmond Cannabis Co.

Social and cultural shifts accompanied by changes in laws spark new opportunities

Cannabis

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

<div>
 
 Toronto-based Revive Therapeutics is a cannabinoid pharmaceutical company developing therapeutics for rare and infectious diseases. With the acquisition of Psilocin Pharma in February 2020, the company entered the psychedelic market and intends to advance psilocybin-based therapeutics targeting various diseases. The acquisition gave Revive ownership of the intellectual property for psilocybin-based manufacturing methods. Revive Therapeutics&rsquo; non-psychedelic drug candidates include Bucillamine to treat Covid-19 and liver diseases.&nbsp;
 
 
 The company is traded on the Canadian Securities Exchange (CSE) under the ticker symbol &ldquo;RVV&rdquo; and commenced trading on the over-the-counter (OTCQB) markets in June 2021 under the ticker symbol &ldquo;RVVTF&rdquo;
 
 
 Key customers and partnerships
 
 
 In November 2020, the company entered into a partnership with PharmaTher to gain access to the latter&rsquo;s artificial intelligence (AI) drug discovery platform. Revive will leverage the platform to discover new uses of undisclosed psychedelic compounds, which could help the company expand its drug pipeline. Further in 
 <a href="https://sp-edge.com/updates/16151">
 February 2023
 </a>
 , the company partnered with PharmaTher, to study the delivery of 3,4-methylenedioxy​methamphetamine (MDMA) using PharmaTher&rsquo;s microneedle patch technology as an alternative to existing oral treatments. 
 
</div>

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies conducting research on psychedelic compounds and developing novel therapeutics.

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

<div>
 
 Revive Therapeutics Ltd. is a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and psychedelic treatments. The company's primary areas of focus include the potential use of Bucillamine for treating severe influenza and Covid-19, as well as the development of psilocybin-based therapeutics for various diseases and disorders. Revive is advancing a psychedelic pharmaceuticals pipeline, which includes a proprietary oral thin film delivery technology for psilocybin-based therapeutics developed in collaboration with the University of Wisconsin-Madison. The company is also working on a novel biosynthetic version of psilocybin using a natural biosynthesis enzymatic platform developed by Dr. Gavin Williams at North Carolina State University.
 
 
 
 
 In addition to its psychedelics research, Revive's cannabinoid pharmaceutical portfolio targets rare inflammatory diseases. The company has received FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis and to prevent ischemia and reperfusion injury from organ transplantation. Revive is prioritizing drug development efforts to take advantage of regulatory incentives awarded by the FDA, such as Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations. In January 2021, Revive was included in the First Psychedelics Exchange Traded Fund, managed by Horizons ETF Management, recognizing its position in the field of psychedelic pharmaceuticals.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 
 Revive Therapeutics has established several key partnerships to advance its research and development efforts. The company collaborates with the University of Wisconsin-Madison on the development of its oral thin film delivery technology for psilocybin and is conducting a clinical study evaluating psilocybin in the treatment of methamphetamine use disorder. In April 2019, Revive entered into a collaboration and royalty agreement with Richmond Cannabis Co., a late-stage Licensed Producer applicant under the Cannabis Act, to establish a cannabis oil production license and commercialize high-quality cannabis products for the wellness and medical markets. The company also has a research partnership with Dr. Gavin Williams at North Carolina State University for the development of a biosynthetic version of psilocybin. Additionally, Revive is working with PharmaTher Inc. on psilocybin research and development initiatives.
 
</div>

Cresco Labs is a vertically integrated multistate cannabis operator with a focus on delivering consistent quality products across its portfolio of branded offerings. The company cultivates, processes, and distributes a diverse range of cannabis products, including flower, vapes, concentrates, edibles, and pre-rolls. Cresco Labs operates under multiple brands, such as Cresco, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's Edibles, and Remedi, catering to various consumer preferences and occasions.
Cresco's cultivation practices involve rigorous phenotype hunting and small-batch cultivation to ensure premium quality. Their products are meticulously hand-trimmed and expertly cared for throughout the process. The company's brand portfolio aims to provide consistent, reliable, and enjoyable cannabis experiences for consumers, whether they are familiar with the plant or new to it.
As of December 2023, Cresco Labs operated in numerous states across the US, with 21 production facilities and 49 dispensaries under the Sunnyside retail banner. The company has implemented operational changes to improve its environmental impact and formed partnerships, such as with Temple University, to explore the potential healing properties of cannabis.
In February 2023, Cresco Labs expanded its retail presence by opening a new Sunnyside dispensary in Daytona Beach, Florida, marking its 23rd location in the state and 58th nationwide. The company reported generating revenue of approximately USD 822 million for the full year 2021.

Cresco Labs

<div>
 
 TerrAscend is a leading North American cannabis operator with vertically integrated operations in California, Maryland, Michigan, New Jersey, and Pennsylvania, as well as retail operations in Canada. The company focuses on growing high-quality cannabis, promoting its health benefits, and offering a diverse range of products tailored to the needs of medical patients and adult-use consumers. TerrAscend utilizes advanced cultivation techniques, innovative cannabis cultivars, and strategic technology investments to produce premium cannabis products.
 
 
 
 
 In March 2022, TerrAscend completed the acquisition of Gage Growth Corp., a prominent cannabis brand and operator, in a deal valued at over USD 545 million. This strategic acquisition aimed to create a differentiated and compelling player in the North American cannabis market, combining TerrAscend's proven cultivation and manufacturing expertise with Gage's top-selling brands and exceptional retail experiences.
 
 
 
 
 As of January 2023, TerrAscend operated 32 dispensaries nationwide under its award-winning retail concepts, The Apothecarium and Gage. The company's portfolio includes several synergistic businesses and brands, such as Gage Cannabis, Ilera healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. In May 2023, TerrAscend strengthened its balance sheet by selling a facility in Canada for CADUSD 19.7 million, using the proceeds to pay down existing debt.
 
</div>

TerrAscend

Holistic Industries is a multistate cannabis company that specializes in cultivating, manufacturing, and distributing a diverse range of premium cannabis products. Their portfolio includes Liberty Cannabis flower strains, meticulously grown and sustainably cultivated to offer an exceptional experience across indica, sativa, and hybrid varieties. Holistic Industries also produces Strane vape cartridges, crafted with CO2-extracted cannabis oil and all-natural terpenes for a smooth and flavorful vaping experience. Additionally, they offer Strane concentrates in various forms, such as shatter, wax, and live resin, catering to consumers seeking potency and purity. The company's product line further encompasses Holistic Remedies, a collection of topicals and tinctures, as well as elixirs and edibles, including cannabis-infused sparkling waters and chocolates, providing precise dosing and delicious flavors.
Holistic Industries places a strong emphasis on quality control, subjecting their products to rigorous testing processes to ensure they are free from contaminants, pesticides, and consistently meet high standards. The company collaborates with scientists, medical professionals, and researchers to develop cutting-edge cannabis formulations and products. Furthermore, Holistic Industries prioritizes sustainable practices, demonstrating a commitment to environmental responsibility.
In December 2023, Holistic Industries launched the Garcia Hand Picked cannabis brand, a collaboration with the family of Grateful Dead guitarist Jerry Garcia, after years of sampling countless strains to find one worthy of his name.

Holistic Industries

<div>
 
 Flower One is a Nevada-based cannabis cultivator and producer focused on the state's lucrative cannabis market. The company operates a 455,000 square-foot greenhouse and production facility, the largest in Nevada. As of June 2019, Flower One commenced continuous harvest operations, capable of producing 140,000 lbs (62,500 kg) of dry flower annually from over 100,000 plants across eight flower zones per crop cycle. Additionally, Flower One owns North Las Vegas Organics, a 25,000 square-foot indoor cultivation facility with nine grow rooms that can cultivate 4,500 plants per cycle.
 
 
 
 
 Flower One produces a diverse range of cannabis products, including flower, full-spectrum oils, distillates, pre-rolls, concentrates, edibles, and topicals for various brands. In October 2018, the company acquired NLV Organics, a Las Vegas-based cannabis cultivation business, for USD 27 million, expanding its footprint in Nevada's rapidly growing cannabis industry. As of June 2022, Flower One appointed Tim Shoemake as its new Chief Operating Officer, leveraging his over 25 years of experience in global agriculture and food and beverage manufacturing. Flower One trades on the Canadian Securities Exchange under the ticker symbol &quot;FONE&quot;.
 
 
 
</div>

Flower One

Grassroots Cannabis is a vertically integrated multi-state cannabis operator based in Illinois. The company specializes in the cultivation, processing, and retail distribution of medical and recreational cannabis products. Grassroots operates over 20 dispensaries under brands like Herbology, Greenhouse, and Windy City Cannabis across six states, including Illinois, Maryland, Ohio, and Pennsylvania.
The company takes pride in its cultivation process, which involves cloning from mother plants, vegetative growth, flowering, pre-harvest flushing, harvesting, drying, and curing to ensure high-quality cannabis flower, concentrates, vapes, and edibles. Grassroots' product offerings encompass a wide range of strains, both indica and sativa, as well as hybrids. Notable strains include Bubba Diagonal, White OG, Ghost Rider, and Candyland, among others.
In July 2019, Curaleaf, a Massachusetts-based cannabis company, announced plans to acquire Grassroots for USD 875 million in stock and cash. The acquisition expanded Curaleaf's presence from 12 states to 19, adding key markets like Illinois and Pennsylvania to its portfolio. Upon completion of the deal, the combined entity would have 131 dispensary licenses, 68 operational locations, 20 cultivation sites, and 26 processing facilities.

Grassroots Cannabis

Companies that specialize in growing and refining cannabis.

Companies that distribute and sell cannabis and cannabis-related products.

Companies that extract cannabinoids to create cannabis-related medication or edibles.

Companies that carry out medical consultations to prescribe cannabis.

Companies that either provide consultations, educate, or carry out testing of cannabis products.

Some startups employ sustainable farming practices when cultivating cannabis

<div>
 Ontario-based company Revive Therapeutics plans a private placement to raise CAD 3 million. This is expected to close by February 2024. The funding will be used for clinical work, possible repayments, and working capital purposes.
</div>

Revive Therapeutics

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless